Highlight Therapeutics SL Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Highlight Therapeutics SL's estimated annual revenue is currently $3.4M per year.(i)
  • Highlight Therapeutics SL's estimated revenue per employee is $155,000

Employee Data

  • Highlight Therapeutics SL has 22 Employees.(i)
  • Highlight Therapeutics SL grew their employee count by -8% last year.

Highlight Therapeutics SL's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$99.4M45840%N/AN/A
#2
$20.6M13322%N/AN/A
#3
$156.1M146-70%$145MN/A
#4
$3.5M45-25%$150MN/A
#5
$1.6M210%$459.5MN/A
#6
$67.3M31016%$180.7MN/A
#7
$8.5M55-2%N/AN/A
#8
$256.3M10259%$168.5MN/A
#9
$2.8M18-33%N/AN/A
#10
$9.1M59-9%N/AN/A
Add Company

What Is Highlight Therapeutics SL?

Highlight, formerly known as Bioncotech Therapeutics S.L, is a private, clinical-stage company dedicated to unlocking the full potential of immuno-oncology. Its lead drug candidate BO-112 is a best-in-class RNA-based therapy which has been demonstrated to initiate a powerful immune response, leveraging a unique multi-target approach to turn ‘cold' tumors ‘hot' and therefore visible to the immune system. It has the potential to rescue patients who are resistant to current checkpoint inhibitor therapy. BO-112 is currently being investigated in a range of clinical trials as a monotherapy and in combination with checkpoint inhibitors. In addition to in-house research, Highlight Therapeutics has a number of external collaborators, including Merck & Co and UCLA.

keywords:N/A

N/A

Total Funding

22

Number of Employees

$3.4M

Revenue (est)

-8%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Highlight Therapeutics SL News

2022-03-22 - Highlight Therapeutics to present at the American Association ...

Highlight Therapeutics S. L., info highlighttherapeutics.com. Marisol Quintero, CEO. Mo PR Advisory, Tel: +44 (0) 7876...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$3.1M220%N/A
#2
$3.1M22-8%N/A
#3
$1.7M22-33%$173M
#4
$2.2M225%N/A
#5
$1.8M22-27%N/A